Free Trial

Ligand Pharmaceuticals (LGND) Financials

Ligand Pharmaceuticals logo
$106.59 +2.32 (+2.22%)
As of 04/14/2025 04:00 PM Eastern
Annual Income Statements for Ligand Pharmaceuticals

Annual Income Statements for Ligand Pharmaceuticals

This table shows Ligand Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-33 52 -4.03
Consolidated Net Income / (Loss)
-33 52 -4.03
Net Income / (Loss) Continuing Operations
-5.22 54 -4.03
Total Pre-Tax Income
36 64 2.52
Total Operating Income
3.04 12 -23
Total Gross Profit
143 121 156
Total Revenue
196 131 167
Operating Revenue
196 131 167
Total Cost of Revenue
53 11 11
Operating Cost of Revenue
53 11 11
Total Operating Expenses
140 111 179
Selling, General & Admin Expense
70 53 79
Research & Development Expense
36 25 21
Amortization Expense
34 34 33
Other Operating Expenses / (Income)
0.00 0.00 15
Impairment Charge
0.00 0.00 31
Total Other Income / (Expense), net
33 54 25
Interest Expense
1.80 0.66 3.04
Interest & Investment Income
31 54 83
Other Income / (Expense), net
4.19 0.42 -55
Income Tax Expense
41 9.84 6.55
Net Income / (Loss) Discontinued Operations
-28 -1.67 0.00
Basic Earnings per Share
($1.98) $3.02 ($0.22)
Weighted Average Basic Shares Outstanding
16.87M 17.30M 18.29M
Diluted Earnings per Share
($1.98) $2.94 ($0.22)
Weighted Average Diluted Shares Outstanding
16.87M 17.76M 18.29M
Weighted Average Basic & Diluted Shares Outstanding
17.08M 17.71M 19.26M

Quarterly Income Statements for Ligand Pharmaceuticals

This table shows Ligand Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
0.40 -17 42 2.29 -10 18 86 -52 -7.17 -31
Consolidated Net Income / (Loss)
0.40 -17 42 2.29 -10 18 86 -52 -7.17 -31
Net Income / (Loss) Continuing Operations
9.65 -15 44 2.29 -10 18 86 -52 -7.17 -31
Total Pre-Tax Income
12 24 56 3.17 -12 17 113 -65 -6.34 -39
Total Operating Income
12 -20 14 -1.98 3.08 -3.36 2.99 -19 3.14 -9.64
Total Gross Profit
59 -2.45 44 25 33 19 31 42 49 34
Total Revenue
59 50 44 26 33 28 31 42 52 43
Operating Revenue
59 50 44 26 33 28 31 42 52 43
Total Cost of Revenue
0.00 53 0.00 1.67 0.00 8.84 0.00 0.00 2.45 8.63
Total Operating Expenses
47 18 30 27 30 25 28 61 46 44
Selling, General & Admin Expense
15 31 11 11 15 16 11 18 24 26
Research & Development Expense
9.24 9.20 6.66 6.85 5.53 5.49 5.97 5.35 5.68 4.43
Amortization Expense
8.57 8.54 8.54 8.54 8.24 8.34 8.19 8.26 8.26 8.26
Other Operating Expenses / (Income)
14 -31 3.72 - 1.36 - 2.88 2.91 7.81 1.46
Total Other Income / (Expense), net
0.01 44 41 5.15 -15 23 110 -46 -9.48 -30
Interest Expense
0.33 0.24 0.24 0.28 0.00 0.13 0.14 1.27 0.74 0.89
Interest & Investment Income
-0.33 45 41 6.31 -11 18 113 -11 3.75 -22
Other Income / (Expense), net
0.68 -0.79 0.60 -0.87 -4.30 4.99 -2.19 -34 -12 -6.71
Income Tax Expense
2.71 39 12 0.88 -1.87 -1.09 27 -13 0.83 -8.11
Basic Earnings per Share
$0.02 ($1.04) $2.46 $0.13 ($0.59) $1.02 $4.86 ($2.88) ($0.39) ($1.81)
Weighted Average Basic Shares Outstanding
16.89M 16.87M 17.06M 17.28M 17.38M 17.30M 17.73M 18.03M 18.42M 18.29M
Diluted Earnings per Share
$0.02 ($1.04) $2.33 $0.13 ($0.59) $1.07 $4.75 ($2.88) ($0.39) ($1.70)
Weighted Average Diluted Shares Outstanding
17.13M 16.87M 17.97M 17.73M 17.38M 17.76M 18.12M 18.03M 18.42M 18.29M
Weighted Average Basic & Diluted Shares Outstanding
16.89M 17.08M 17.27M 17.36M 17.44M 17.71M 17.96M 18.27M 18.90M 19.26M

Annual Cash Flow Statements for Ligand Pharmaceuticals

This table details how cash moves in and out of Ligand Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
25 -22 49
Net Cash From Operating Activities
138 50 97
Net Cash From Continuing Operating Activities
138 50 97
Net Income / (Loss) Continuing Operations
-33 52 -4.03
Consolidated Net Income / (Loss)
-33 52 -4.03
Depreciation Expense
52 37 35
Amortization Expense
6.27 0.66 1.28
Non-Cash Adjustments To Reconcile Net Income
27 -23 33
Changes in Operating Assets and Liabilities, net
87 -17 31
Net Cash From Investing Activities
164 -12 -144
Net Cash From Continuing Investing Activities
164 -12 -144
Purchase of Property, Plant & Equipment
-18 -3.52 -1.82
Acquisitions
-0.75 -26 -93
Purchase of Investments
-51 -127 -301
Sale and/or Maturity of Investments
234 194 270
Other Investing Activities, net
-0.87 -50 -17
Net Cash From Financing Activities
-276 -60 97
Net Cash From Continuing Financing Activities
-276 -60 97
Repayment of Debt
-261 -78 -0.43
Payment of Dividends
-6.80 0.00 0.00
Issuance of Common Equity
0.00 0.00 37
Other Financing Activities, net
-8.24 18 60
Cash Interest Paid
1.43 0.29 0.26
Cash Income Taxes Paid
12 8.77 19

Quarterly Cash Flow Statements for Ligand Pharmaceuticals

This table details how cash moves in and out of Ligand Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-1.16 41 44 -60 -8.59 3.10 27 -32 45 8.69
Net Cash From Operating Activities
20 53 34 -0.08 7.65 8.07 19 13 37 28
Net Cash From Continuing Operating Activities
20 53 34 -0.08 7.65 8.07 19 13 37 28
Net Income / (Loss) Continuing Operations
0.40 -17 42 2.29 -10 18 86 -52 -7.17 -31
Consolidated Net Income / (Loss)
0.40 -17 42 2.29 -10 18 86 -52 -7.17 -31
Depreciation Expense
13 11 9.50 9.50 8.61 8.92 8.77 8.85 8.99 8.63
Amortization Expense
1.84 1.02 0.26 0.14 0.06 0.21 0.41 0.17 0.57 0.14
Non-Cash Adjustments To Reconcile Net Income
12 -14 -35 3.56 22 -13 -104 85 25 27
Changes in Operating Assets and Liabilities, net
-7.61 73 17 -16 -13 -5.78 27 -29 9.59 24
Net Cash From Investing Activities
19 -7.28 11 7.56 -20 -10 -3.78 -55 -47 -39
Net Cash From Continuing Investing Activities
19 -7.28 11 7.56 -20 -10 -3.78 -55 -47 -39
Purchase of Property, Plant & Equipment
-4.33 -2.13 -2.41 -0.20 -0.49 -0.42 -0.11 -0.41 -0.60 -0.71
Purchase of Investments
-0.58 -12 -40 -49 -18 -20 -78 -99 -32 -93
Sale and/or Maturity of Investments
25 7.01 53 57 25 60 75 47 95 52
Other Investing Activities, net
-0.91 0.01 0.13 0.08 0.14 -50 -0.50 -1.97 -17 2.54
Net Cash From Financing Activities
-41 -5.30 -0.78 -68 3.27 5.32 12 9.49 55 20
Net Cash From Continuing Financing Activities
-41 -5.30 -0.78 -68 3.27 5.32 12 9.49 55 20
Repayment of Debt
-38 0.04 0.00 -77 - -0.95 -0.04 -0.06 -0.21 -0.12
Issuance of Common Equity
- - - - - - - - - 3.11
Other Financing Activities, net
0.80 -2.71 -0.78 9.10 3.27 6.26 12 9.55 21 17
Cash Interest Paid
0.10 0.29 0.00 0.29 - - 0.06 0.05 0.15 0.00
Cash Income Taxes Paid
6.61 5.01 - - 0.01 8.76 - - 12 1.86

Annual Balance Sheets for Ligand Pharmaceuticals

This table presents Ligand Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
763 787 942
Total Current Assets
264 237 332
Cash & Equivalents
45 23 72
Short-Term Investments
167 147 184
Accounts Receivable
30 33 38
Inventories, net
13 24 14
Prepaid Expenses
1.13 1.18 1.93
Current Deferred & Refundable Income Taxes
4.61 6.40 4.07
Other Current Assets
2.27 2.66 17
Plant, Property, & Equipment, net
12 16 15
Total Noncurrent Assets
487 534 595
Long-Term Investments
3.00 49 11
Noncurrent Note & Lease Receivables
4.10 3.39 2.77
Goodwill
106 103 105
Intangible Assets
342 300 267
Noncurrent Deferred & Refundable Income Taxes
8.53 0.21 0.07
Other Noncurrent Operating Assets
23 78 209
Total Liabilities & Shareholders' Equity
763 787 942
Total Liabilities
165 86 111
Total Current Liabilities
99 17 37
Accounts Payable
5.31 2.43 5.23
Accrued Expenses
16 12 28
Current Deferred Revenue
0.36 1.22 1.28
Current Deferred & Payable Income Tax Liabilities
- 0.00 1.20
Other Current Liabilities
0.77 0.67 1.50
Total Noncurrent Liabilities
66 70 74
Noncurrent Deferred Revenue
0.04 1.44 2.25
Noncurrent Deferred & Payable Income Tax Liabilities
31 32 33
Other Noncurrent Operating Liabilities
36 36 39
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
597 701 830
Total Preferred & Common Equity
597 701 830
Preferred Stock
0.00 0.00 0.00
Total Common Equity
597 701 830
Common Stock
148 199 337
Retained Earnings
451 503 499
Accumulated Other Comprehensive Income / (Loss)
-0.98 -0.82 -5.94

Quarterly Balance Sheets for Ligand Pharmaceuticals

This table presents Ligand Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
1,051 811 758 769 914 866 955
Total Current Assets
220 328 277 254 369 312 309
Cash & Equivalents
4.12 89 28 19 50 18 64
Short-Term Investments
117 194 191 171 261 209 156
Accounts Receivable
65 29 28 36 28 37 34
Inventories, net
22 14 27 25 21 19 17
Current Deferred & Refundable Income Taxes
0.79 0.00 0.00 0.00 0.00 0.00 7.81
Other Current Assets
11 2.33 2.77 2.10 7.31 27 31
Plant, Property, & Equipment, net
33 12 11 16 15 15 15
Total Noncurrent Assets
797 471 470 499 530 539 630
Long-Term Investments
- - - 14 47 13 13
Noncurrent Note & Lease Receivables
14 3.94 3.76 3.57 3.22 3.09 2.94
Goodwill
181 106 106 104 105 105 105
Intangible Assets
517 334 325 315 291 283 275
Noncurrent Deferred & Refundable Income Taxes
36 0.88 8.53 8.53 0.00 0.19 0.08
Other Noncurrent Operating Assets
49 27 27 54 83 134 234
Total Liabilities & Shareholders' Equity
1,051 811 758 769 914 866 955
Total Liabilities
234 165 93 101 107 91 114
Total Current Liabilities
135 99 29 16 18 19 25
Accounts Payable
16 6.14 9.58 2.48 1.89 1.79 4.69
Accrued Expenses
19 15 7.29 11 12 12 16
Current Deferred Revenue
9.55 0.26 - - 1.23 1.20 1.15
Current Deferred & Payable Income Tax Liabilities
9.70 - 11 1.20 1.14 2.09 2.11
Other Current Liabilities
4.17 0.77 1.13 1.41 1.13 1.31 1.22
Total Noncurrent Liabilities
99 66 64 86 90 73 89
Noncurrent Deferred Revenue
5.54 - - - 3.07 2.70 2.51
Noncurrent Deferred & Payable Income Tax Liabilities
30 30 28 33 51 30 46
Other Noncurrent Operating Liabilities
64 36 36 53 36 40 40
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
816 646 665 668 807 775 841
Total Preferred & Common Equity
816 646 665 668 807 775 841
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
816 646 665 668 807 775 841
Common Stock
349 154 171 184 218 239 309
Retained Earnings
468 493 495 485 589 537 530
Accumulated Other Comprehensive Income / (Loss)
-1.06 -0.94 -0.97 -0.94 -0.91 -0.94 1.75

Annual Metrics and Ratios for Ligand Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Ligand Pharmaceuticals' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
-18.75% -33.09% 27.28%
EBITDA Growth
-61.47% -23.82% -182.77%
EBIT Growth
-92.49% 71.11% -727.17%
NOPAT Growth
-100.40% 2,393.77% 258.54%
Net Income Growth
-158.39% 256.33% -107.73%
EPS Growth
-159.82% 248.48% -107.48%
Operating Cash Flow Growth
74.94% -64.04% 95.75%
Free Cash Flow Firm Growth
-45.25% -108.59% -286.33%
Invested Capital Growth
-23.19% 4.78% 17.06%
Revenue Q/Q Growth
7.39% -14.51% 9.65%
EBITDA Q/Q Growth
-49.06% 64.84% -72.29%
EBIT Q/Q Growth
-88.65% 221.64% -29.64%
NOPAT Q/Q Growth
-100.93% 805.04% 388.21%
Net Income Q/Q Growth
-56.68% 216.45% -108.91%
EPS Q/Q Growth
-55.91% 254.22% -108.63%
Operating Cash Flow Q/Q Growth
23.06% -47.80% 26.63%
Free Cash Flow Firm Q/Q Growth
69.59% -103.87% 70.87%
Invested Capital Q/Q Growth
-40.46% 3.86% -7.40%
Profitability Metrics
- - -
Gross Margin
73.08% 91.99% 93.37%
EBITDA Margin
33.14% 37.73% -24.53%
Operating Margin
1.55% 9.09% -13.53%
EBIT Margin
3.68% 9.41% -46.38%
Profit (Net Income) Margin
-17.00% 39.72% -2.41%
Tax Burden Percent
-92.64% 81.93% -160.13%
Interest Burden Percent
498.49% 515.01% -3.25%
Effective Tax Rate
114.49% 15.46% 260.13%
Return on Invested Capital (ROIC)
-0.08% 2.15% 6.93%
ROIC Less NNEP Spread (ROIC-NNEP)
18.14% -21.36% 23.46%
Return on Net Nonoperating Assets (RNNOA)
-4.62% 5.89% -7.46%
Return on Equity (ROE)
-4.70% 8.03% -0.53%
Cash Return on Invested Capital (CROIC)
26.15% -2.53% -8.78%
Operating Return on Assets (OROA)
0.70% 1.60% -8.97%
Return on Assets (ROA)
-3.24% 6.73% -0.47%
Return on Common Equity (ROCE)
-4.70% 8.03% -0.53%
Return on Equity Simple (ROE_SIMPLE)
-5.58% 7.44% -0.49%
Net Operating Profit after Tax (NOPAT)
-0.44 10 36
NOPAT Margin
-0.22% 7.69% 21.66%
Net Nonoperating Expense Percent (NNEP)
-18.22% 23.51% -16.53%
Return On Investment Capital (ROIC_SIMPLE)
-0.07% 1.44% 4.36%
Cost of Revenue to Revenue
26.92% 8.01% 6.63%
SG&A Expenses to Revenue
35.70% 40.20% 47.06%
R&D to Revenue
18.39% 18.69% 12.82%
Operating Expenses to Revenue
71.53% 84.52% 106.90%
Earnings before Interest and Taxes (EBIT)
7.22 12 -78
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
65 50 -41
Valuation Ratios
- - -
Price to Book Value (P/BV)
1.89 1.78 2.44
Price to Tangible Book Value (P/TBV)
7.56 4.18 4.42
Price to Revenue (P/Rev)
5.75 9.48 12.11
Price to Earnings (P/E)
0.00 23.88 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 4.19% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.16 2.13 3.12
Enterprise Value to Revenue (EV/Rev)
5.05 7.81 10.52
Enterprise Value to EBITDA (EV/EBITDA)
15.23 20.70 0.00
Enterprise Value to EBIT (EV/EBIT)
137.09 82.97 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 101.59 48.55
Enterprise Value to Operating Cash Flow (EV/OCF)
7.18 20.69 18.11
Enterprise Value to Free Cash Flow (EV/FCFF)
7.16 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.13 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.25 -0.28 -0.32
Leverage Ratio
1.45 1.19 1.13
Compound Leverage Factor
7.24 6.15 -0.04
Debt to Total Capital
11.38% 0.00% 0.00%
Short-Term Debt to Total Capital
11.38% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
88.62% 100.00% 100.00%
Debt to EBITDA
1.18 0.00 0.00
Net Debt to EBITDA
-2.12 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
-174.25 0.00 0.00
Net Debt to NOPAT
313.93 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
5.47 10.11 11.93
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
2.67 14.15 8.93
Quick Ratio
2.45 12.11 7.94
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
138 -12 -46
Operating Cash Flow to CapEx
769.12% 1,408.04% 5,329.32%
Free Cash Flow to Firm to Interest Expense
76.84 -18.11 -15.11
Operating Cash Flow to Interest Expense
76.63 75.57 31.95
Operating Cash Flow Less CapEx to Interest Expense
66.66 70.21 31.36
Efficiency Ratios
- - -
Asset Turnover
0.19 0.17 0.19
Accounts Receivable Turnover
3.39 4.15 4.69
Inventory Turnover
2.60 0.56 0.58
Fixed Asset Turnover
15.29 9.35 10.87
Accounts Payable Turnover
7.71 2.72 2.89
Days Sales Outstanding (DSO)
107.76 88.03 77.85
Days Inventory Outstanding (DIO)
140.33 646.93 627.61
Days Payable Outstanding (DPO)
47.36 134.27 126.24
Cash Conversion Cycle (CCC)
200.73 600.69 579.22
Capital & Investment Metrics
- - -
Invested Capital
459 481 563
Invested Capital Turnover
0.37 0.28 0.32
Increase / (Decrease) in Invested Capital
-139 22 82
Enterprise Value (EV)
990 1,026 1,758
Market Capitalization
1,128 1,245 2,025
Book Value per Share
$35.37 $40.20 $43.95
Tangible Book Value per Share
$8.84 $17.09 $24.27
Total Capital
674 701 830
Total Debt
77 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-138 -220 -267
Capital Expenditures (CapEx)
18 3.52 1.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)
30 50 38
Debt-free Net Working Capital (DFNWC)
241 221 294
Net Working Capital (NWC)
165 221 294
Net Nonoperating Expense (NNE)
33 -42 40
Net Nonoperating Obligations (NNO)
-138 -220 -267
Total Depreciation and Amortization (D&A)
58 37 37
Debt-free, Cash-free Net Working Capital to Revenue
15.09% 38.33% 22.91%
Debt-free Net Working Capital to Revenue
123.05% 168.03% 176.18%
Net Working Capital to Revenue
83.97% 168.03% 176.18%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.98) $3.02 ($0.22)
Adjusted Weighted Average Basic Shares Outstanding
16.87M 17.30M 18.29M
Adjusted Diluted Earnings per Share
($1.98) $2.94 ($0.22)
Adjusted Weighted Average Diluted Shares Outstanding
16.87M 17.76M 18.29M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
17.08M 17.71M 19.26M
Normalized Net Operating Profit after Tax (NOPAT)
2.13 10 5.58
Normalized NOPAT Margin
1.08% 7.69% 3.34%
Pre Tax Income Margin
18.35% 48.48% 1.51%
Debt Service Ratios
- - -
EBIT to Interest Expense
4.02 18.84 -25.53
NOPAT to Interest Expense
-0.24 15.39 11.92
EBIT Less CapEx to Interest Expense
-5.95 13.48 -26.13
NOPAT Less CapEx to Interest Expense
-10.21 10.02 11.32
Payout Ratios
- - -
Dividend Payout Ratio
-20.38% 0.00% 0.00%
Augmented Payout Ratio
-20.38% 0.00% 0.00%

Quarterly Metrics and Ratios for Ligand Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Ligand Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-8.66% 36.60% 20.44% -47.40% -44.50% -44.22% -29.56% 57.52% 57.64% 52.35%
EBITDA Growth
-19.43% -116.21% 23.46% -73.46% -73.73% 223.09% -59.43% -743.45% -97.17% -170.51%
EBIT Growth
-26.00% -158.76% 237.47% -126.67% -109.39% 107.81% -94.62% -1,742.54% -665.30% -1,102.15%
NOPAT Growth
-31.79% -58.40% 647.14% -111.37% -77.64% -129.52% -79.66% -833.62% 2.11% -88.84%
Net Income Growth
-97.06% -222.84% 372.66% 355.87% -2,642.82% 204.02% 105.34% -2,366.86% 30.19% -270.93%
EPS Growth
-97.50% -215.15% 356.04% 360.00% -3,050.00% 202.88% 103.86% -2,315.38% 33.90% -258.88%
Operating Cash Flow Growth
2.32% 93.44% -34.73% -100.69% -62.68% -84.92% -44.82% 16,336.59% 377.77% 253.02%
Free Cash Flow Firm Growth
110.36% -12.21% 6,455.36% 645.71% 606.88% -116.94% -101.86% -131.85% -146.02% -247.73%
Invested Capital Growth
-4.25% -23.19% -42.48% -42.05% -39.93% 4.78% 1.93% 20.02% 31.28% 17.06%
Revenue Q/Q Growth
18.14% -14.93% -12.71% -40.05% 24.66% -14.50% 10.24% 34.07% 24.76% -17.37%
EBITDA Q/Q Growth
11.00% -130.83% 381.25% -72.42% 9.86% 44.44% 3.55% -537.49% 100.48% -3,692.89%
EBIT Q/Q Growth
21.55% -260.49% 170.88% -119.29% 57.21% 233.47% -42.36% -6,710.93% 82.23% -74.78%
NOPAT Q/Q Growth
-23.54% 25.60% -7.81% -112.84% 250.45% -265.80% 163.51% -689.31% 116.46% -406.62%
Net Income Q/Q Growth
145.14% -4,427.97% 339.91% -94.54% -548.60% 277.05% 373.60% -160.26% 86.18% -333.46%
EPS Q/Q Growth
140.00% -5,300.00% 324.04% -94.42% -553.85% 281.36% 343.93% -160.63% 86.46% -335.90%
Operating Cash Flow Q/Q Growth
72.50% 160.98% -36.51% -100.24% 9,424.39% 5.48% 132.26% -28.92% 174.37% -22.06%
Free Cash Flow Firm Q/Q Growth
1.60% 243.53% 123.15% -4.26% -3.69% -108.23% 75.54% -1,542.17% -39.15% 37.78%
Invested Capital Q/Q Growth
0.27% -40.46% -4.11% 1.23% 3.94% 3.86% -6.72% 19.18% 13.70% -7.40%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% -4.85% 100.00% 93.67% 100.00% 68.53% 100.00% 100.00% 95.27% 79.85%
EBITDA Margin
47.85% -17.34% 55.86% 25.70% 22.65% 38.26% 32.17% -104.98% 0.41% -17.71%
Operating Margin
20.84% -39.89% 32.30% -7.52% 9.36% -11.95% 9.65% -45.99% 6.07% -22.51%
EBIT Margin
21.98% -41.47% 33.67% -10.83% -3.72% 5.80% 2.57% -126.71% -18.05% -38.18%
Profit (Net Income) Margin
0.68% -34.70% 95.38% 8.69% -31.26% 64.72% 278.07% -124.99% -13.84% -72.62%
Tax Burden Percent
3.27% -72.43% 75.53% 72.22% 84.59% 106.38% 75.93% 79.39% 113.14% 79.31%
Interest Burden Percent
94.90% -115.55% 375.04% -111.03% 993.78% 1,048.25% 14,252.14% 124.26% 67.78% 239.83%
Effective Tax Rate
21.93% 160.21% 21.47% 27.78% 0.00% -6.38% 24.07% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
3.77% 8.92% 8.57% -1.61% 1.63% -3.55% 1.95% -8.76% 1.21% -5.04%
ROIC Less NNEP Spread (ROIC-NNEP)
39.88% 25.29% -17.83% -4.56% 11.60% -15.71% -27.82% 8.03% 5.49% 4.96%
Return on Net Nonoperating Assets (RNNOA)
-1.25% -6.44% 2.89% 0.78% -1.95% 4.33% 10.79% -2.56% -1.59% -1.58%
Return on Equity (ROE)
2.52% 2.47% 11.46% -0.82% -0.32% 0.78% 12.74% -11.32% -0.38% -6.62%
Cash Return on Invested Capital (CROIC)
10.34% 26.15% 55.21% 53.57% 49.66% -2.53% -1.79% -20.85% -29.40% -8.78%
Operating Return on Assets (OROA)
3.46% -7.90% 7.16% -2.13% -0.63% 0.98% 0.35% -20.82% -3.19% -7.38%
Return on Assets (ROA)
0.11% -6.61% 20.28% 1.70% -5.28% 10.97% 38.14% -20.54% -2.45% -14.04%
Return on Common Equity (ROCE)
2.52% 2.47% 11.46% -0.82% -0.32% 0.78% 12.74% -11.32% -0.38% -6.62%
Return on Equity Simple (ROE_SIMPLE)
-2.61% 0.00% 3.71% 4.08% 2.47% 0.00% 11.95% 5.44% 5.38% 0.00%
Net Operating Profit after Tax (NOPAT)
9.63 12 11 -1.43 2.15 -3.57 2.27 -13 2.20 -6.75
NOPAT Margin
16.27% 24.02% 25.37% -5.43% 6.56% -12.71% 7.32% -32.19% 4.25% -15.76%
Net Nonoperating Expense Percent (NNEP)
-36.11% -16.38% 26.39% 2.95% -9.97% 12.16% 29.77% -16.79% -4.29% -10.00%
Return On Investment Capital (ROIC_SIMPLE)
- 1.79% - - - -0.51% - - - -0.81%
Cost of Revenue to Revenue
0.00% 104.85% 0.00% 6.33% 0.00% 31.47% 0.00% 0.00% 4.73% 20.15%
SG&A Expenses to Revenue
25.19% 61.79% 24.68% 42.81% 44.59% 56.91% 35.35% 42.43% 47.24% 59.81%
R&D to Revenue
15.60% 18.25% 15.15% 26.00% 16.83% 19.53% 19.28% 12.89% 10.95% 10.34%
Operating Expenses to Revenue
79.16% 35.04% 67.70% 101.19% 90.64% 88.03% 90.35% 145.99% 89.21% 102.36%
Earnings before Interest and Taxes (EBIT)
13 -21 15 -2.86 -1.22 1.63 0.80 -53 -9.35 -16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
28 -8.74 25 6.78 7.44 11 9.97 -44 0.21 -7.58
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
1.78 1.89 1.94 1.87 1.56 1.78 1.60 1.95 2.17 2.44
Price to Tangible Book Value (P/TBV)
12.31 7.56 6.08 5.33 4.17 4.18 3.16 3.91 3.97 4.42
Price to Revenue (P/Rev)
7.96 5.75 6.17 6.92 6.77 9.48 10.94 11.34 12.00 12.11
Price to Earnings (P/E)
0.00 0.00 52.40 45.86 63.10 23.88 13.43 35.92 40.42 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 1.91% 2.18% 1.58% 4.19% 7.44% 2.78% 2.47% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.83 2.16 2.38 2.30 1.80 2.13 2.09 2.38 2.62 3.12
Enterprise Value to Revenue (EV/Rev)
7.71 5.05 5.16 5.70 5.44 7.81 7.92 9.54 10.47 10.52
Enterprise Value to EBITDA (EV/EBITDA)
11.04 15.23 15.07 20.15 27.80 20.70 27.70 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
22.13 137.09 59.53 251.67 0.00 82.97 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
29.82 0.00 136.38 533.65 0.00 101.59 1,630.29 0.00 0.00 48.55
Enterprise Value to Operating Cash Flow (EV/OCF)
12.58 7.18 8.77 9.52 8.80 20.69 27.26 26.67 20.82 18.11
Enterprise Value to Free Cash Flow (EV/FCFF)
17.29 7.16 3.15 3.15 2.72 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.09 0.13 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.03 -0.25 -0.16 -0.17 -0.17 -0.28 -0.39 -0.32 -0.29 -0.32
Leverage Ratio
1.43 1.45 1.33 1.25 1.23 1.19 1.19 1.13 1.14 1.13
Compound Leverage Factor
1.35 -1.68 4.99 -1.39 12.19 12.51 169.21 1.40 0.77 2.71
Debt to Total Capital
8.58% 11.38% 10.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
8.58% 11.38% 10.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
91.42% 88.62% 89.38% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.60 1.18 1.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
-0.35 -2.12 -2.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
1.62 -174.25 9.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
-0.95 313.93 -26.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
4.66 5.35 6.08 9.55 7.61 10.06 8.73 11.19 10.91 12.15
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
1.63 2.67 3.32 9.42 16.15 14.15 20.70 16.82 12.49 8.93
Quick Ratio
1.38 2.45 3.15 8.41 14.40 12.11 19.03 14.24 10.25 7.94
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
44 151 336 322 310 -26 -6.25 -103 -143 -89
Operating Cash Flow to CapEx
473.30% 2,509.24% 1,406.30% -40.39% 1,570.02% 1,934.05% 17,840.00% 3,263.24% 6,129.19% 3,998.74%
Free Cash Flow to Firm to Interest Expense
132.19 628.21 1,401.86 1,134.23 310,236.60 -195.00 -44.31 -80.92 -192.68 -100.15
Operating Cash Flow to Interest Expense
61.71 222.80 141.45 -0.29 7,646.00 61.56 132.85 10.50 49.30 32.10
Operating Cash Flow Less CapEx to Interest Expense
48.67 213.92 131.39 -1.00 7,159.00 58.38 132.11 10.18 48.49 31.30
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.16 0.19 0.21 0.20 0.17 0.17 0.14 0.16 0.18 0.19
Accounts Receivable Turnover
2.82 3.39 5.74 3.99 3.04 4.15 4.11 4.08 4.34 4.69
Inventory Turnover
0.43 2.60 2.67 2.11 2.28 0.56 0.59 0.39 0.54 0.58
Fixed Asset Turnover
7.01 15.29 11.22 8.50 6.19 9.35 8.80 10.13 9.75 10.87
Accounts Payable Turnover
1.04 7.71 8.06 3.79 5.94 2.72 2.62 1.55 3.15 2.89
Days Sales Outstanding (DSO)
129.33 107.76 63.59 91.58 120.21 88.03 88.88 89.52 84.20 77.85
Days Inventory Outstanding (DIO)
842.48 140.33 136.89 173.07 159.80 646.93 613.68 940.63 680.93 627.61
Days Payable Outstanding (DPO)
352.09 47.36 45.28 96.23 61.49 134.27 139.38 234.75 115.86 126.24
Cash Conversion Cycle (CCC)
619.72 200.73 155.21 168.42 218.52 600.69 563.19 795.40 649.27 579.22
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
771 459 440 446 463 481 449 535 608 563
Invested Capital Turnover
0.23 0.37 0.34 0.30 0.25 0.28 0.27 0.27 0.28 0.32
Increase / (Decrease) in Invested Capital
-34 -139 -325 -324 -308 22 8.52 89 145 82
Enterprise Value (EV)
1,409 990 1,050 1,026 835 1,026 937 1,274 1,596 1,758
Market Capitalization
1,454 1,128 1,256 1,245 1,040 1,245 1,294 1,514 1,829 2,025
Book Value per Share
$48.35 $35.37 $37.85 $38.49 $38.48 $40.20 $45.55 $43.15 $46.04 $43.95
Tangible Book Value per Share
$6.99 $8.84 $12.11 $13.54 $14.36 $17.09 $23.15 $21.53 $25.24 $24.27
Total Capital
893 674 723 665 668 701 807 775 841 830
Total Debt
77 77 77 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-45 -138 -206 -219 -204 -220 -358 -240 -233 -267
Capital Expenditures (CapEx)
4.33 2.13 2.41 0.20 0.49 0.42 0.11 0.41 0.60 0.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)
40 30 23 28 48 50 41 67 65 38
Debt-free Net Working Capital (DFNWC)
162 241 306 247 238 221 351 294 285 294
Net Working Capital (NWC)
85 165 229 247 238 221 351 294 285 294
Net Nonoperating Expense (NNE)
9.23 30 -31 -3.72 12 -22 -84 39 9.37 24
Net Nonoperating Obligations (NNO)
-45 -138 -206 -219 -204 -220 -358 -240 -233 -267
Total Depreciation and Amortization (D&A)
15 12 9.76 9.63 8.67 9.12 9.17 9.02 9.56 8.76
Debt-free, Cash-free Net Working Capital to Revenue
22.10% 15.09% 11.48% 15.72% 31.10% 38.33% 34.23% 50.02% 42.63% 22.91%
Debt-free Net Working Capital to Revenue
88.53% 123.05% 150.24% 137.44% 155.13% 168.03% 296.75% 220.03% 186.73% 176.18%
Net Working Capital to Revenue
46.62% 83.97% 112.55% 137.44% 155.13% 168.03% 296.75% 220.03% 186.73% 176.18%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.02 ($1.04) $2.46 $0.13 ($0.59) $1.02 $4.86 ($2.88) ($0.39) ($1.81)
Adjusted Weighted Average Basic Shares Outstanding
16.89M 16.87M 17.06M 17.28M 17.38M 17.30M 17.73M 18.03M 18.42M 18.29M
Adjusted Diluted Earnings per Share
$0.02 ($1.04) $2.33 $0.13 ($0.59) $1.07 $4.75 ($2.88) ($0.39) ($1.70)
Adjusted Weighted Average Diluted Shares Outstanding
17.13M 16.87M 17.97M 17.73M 17.38M 17.76M 18.12M 18.03M 18.42M 18.29M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
16.89M 17.08M 17.27M 17.36M 17.44M 17.71M 17.96M 18.27M 18.90M 19.26M
Normalized Net Operating Profit after Tax (NOPAT)
9.63 -14 11 -1.43 2.15 -2.35 2.27 5.17 2.20 -6.75
Normalized NOPAT Margin
16.27% -27.93% 25.37% -5.43% 6.56% -8.36% 7.32% 12.46% 4.25% -15.76%
Pre Tax Income Margin
20.86% 47.91% 126.28% 12.03% -36.95% 60.84% 366.22% -157.45% -12.23% -91.56%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
39.21 -87.05 61.70 -10.06 -1,222.00 12.45 5.65 -41.50 -12.62 -18.43
NOPAT to Interest Expense
29.02 50.42 46.48 -5.04 2,154.60 -27.27 16.09 -10.54 2.97 -7.61
EBIT Less CapEx to Interest Expense
26.17 -95.93 51.64 -10.77 -1,709.00 9.27 4.90 -41.82 -13.43 -19.23
NOPAT Less CapEx to Interest Expense
15.98 41.54 36.42 -5.76 1,667.60 -30.45 15.35 -10.87 2.16 -8.41
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% -20.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -20.38% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Ligand Pharmaceuticals' Financials

When does Ligand Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Ligand Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Ligand Pharmaceuticals' net income changed over the last 2 years?

Ligand Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$4.03 million in 2024, falling from -$33.36 million in 2022. The previous period was $52.15 million in 2023.

What is Ligand Pharmaceuticals's operating income?
Ligand Pharmaceuticals's total operating income in 2024 was -$22.61 million, based on the following breakdown:
  • Total Gross Profit: $156.06 million
  • Total Operating Expenses: $178.67 million
How has Ligand Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Ligand Pharmaceuticals' total revenue changed from $196.25 million in 2022 to $167.13 million in 2024, a change of -14.8%.

How much debt does Ligand Pharmaceuticals have?

Ligand Pharmaceuticals' total liabilities were at $111.34 million at the end of 2024, a 29.0% increase from 2023, and a 32.6% decrease since 2022.

How much cash does Ligand Pharmaceuticals have?

In the past 2 years, Ligand Pharmaceuticals' cash and equivalents has ranged from $22.95 million in 2023 to $72.31 million in 2024, and is currently $72.31 million as of their latest financial filing in 2024.

How has Ligand Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Ligand Pharmaceuticals' book value per share changed from 35.37 in 2022 to 43.95 in 2024, a change of 24.3%.

Remove Ads


This page (NASDAQ:LGND) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners